Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bayovac SRS is an inactivated veterinary vaccine (bacterin) developed for the aquaculture industry to protect salmonid fish against Salmon Rickettsial Septicaemia (SRS), a severe systemic disease caused by the Gram-negative intracellular bacterium *Piscirickettsia salmonis*. SRS is a major cause of mortality in farmed salmon, particularly in the Chilean aquaculture sector. The vaccine works by inducing active immunization through the presentation of inactivated bacterial antigens, which stimulates the production of specific antibodies and primes the cellular immune response. Originally developed by Bayer Animal Health, the product is typically administered via intraperitoneal injection to provide long-lasting protection during the seawater growth phase of the fish.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bayovac SRS.